Tarlatzis B C, Bili H
1st Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki and IVF Center, Geniki Kliniki, Greece.
Hum Reprod. 1998 Apr;13 Suppl 1:165-77. doi: 10.1093/humrep/13.suppl_1.165.
Intracytoplasmic sperm injection (ICSI) has revolutionized the treatment of male infertility, since normal fertilization and ongoing pregnancies can be achieved with severely affected spermatozoa. Hence, the application of ICSI is rapidly expanding around the world, necessitating an accurate assessment of the efficacy and safety of this novel technique. The European Society of Human Reproduction and Embryology (ESHRE) Task Force is gathering data annually on the clinical results, the pregnancy outcome and the follow-up of children born after ICSI using ejaculated, epididymal and testicular spermatozoa, in order to be able to provide reliable information on these important issues. During the 3 years 1993-1995, the number of centres performing ICSI increased from 35 to 101, and the total number of ICSI cycles performed per year rose from 3157 to 23932. The incidence of oocytes damaged by the procedure remained low (<10%) and the fertilization rates obtained with ejaculated, epididymal and testicular spermatozoa in 1995 were 64, 62.5 and 52% respectively. Thus, approximately 90% of the couples had an embryo transfer and the viable pregnancy rate was 21% for ejaculated, 22% for epididymal and 19% for testicular spermatozoa (with 25-30% multiple pregnancies). Furthermore, 3149 transfers of frozen-thawed embryos were performed and 7-11% of them resulted in a viable pregnancy. The ICSI results were similar during this 3 year period, irrespective of the origin of the spermatozoa. The perinatal outcome of children born after ICSI was not different from those born after in-vitro fertilization (IVF) or natural conception, and was only affected by multiplicity. Moreover, the incidence of major or minor malformations was not increased, but the chromosomal, especially the sex-chromosomal, aberration rate was slightly elevated. To summarize, a very high success rate is obtained by ICSI independently of the source of the spermatozoa, verifying the superiority of ICSI over conventional IVF. The procedure seems to be safe, but further follow-up of the children is necessary in order to be able to assess its safety more accurately.
卵胞浆内单精子注射(ICSI)彻底改变了男性不育症的治疗方式,因为即使是严重受损的精子也能实现正常受精并维持妊娠。因此,ICSI在全球的应用正在迅速扩展,这就需要准确评估这项新技术的有效性和安全性。欧洲人类生殖与胚胎学会(ESHRE)特别工作组每年都在收集有关ICSI临床结果、妊娠结局以及使用射出精子、附睾精子和睾丸精子进行ICSI后出生儿童随访情况的数据,以便能够就这些重要问题提供可靠信息。在1993年至1995年的3年里,进行ICSI的中心数量从35个增加到101个,每年进行的ICSI周期总数从3157个增至23932个。该操作导致卵母细胞受损的发生率仍然很低(<10%),1995年使用射出精子、附睾精子和睾丸精子的受精率分别为64%、62.5%和52%。因此,大约90%的夫妇进行了胚胎移植,使用射出精子的活产妊娠率为21%,附睾精子为22%,睾丸精子为19%(多胎妊娠率为25 - 30%)。此外,还进行了3149次冻融胚胎移植,其中7 - 11%的移植导致了活产妊娠。在这3年期间,无论精子来源如何,ICSI的结果都相似。ICSI后出生儿童的围产期结局与体外受精(IVF)或自然受孕后出生的儿童并无差异,仅受多胎情况影响。此外,主要或轻微畸形的发生率并未增加,但染色体异常,尤其是性染色体异常率略有升高。总之,ICSI无论精子来源如何都能获得很高的成功率,证实了ICSI优于传统IVF。该操作似乎是安全的,但有必要对儿童进行进一步随访,以便更准确地评估其安全性。